Unni LK[au] - Search Results

Year	Number of Results
1984	1
1985	2
1986	1
1987	1
1989	1
1991	2
1992	2
1994	2
1996	1
1998	1
2009	1
2022	0

1

Resurrecting clinical pharmacology as a context for Alzheimer disease drug development.

Becker RE, Unni LK, Greig NH. Becker RE, et al. Among authors: unni lk. Curr Alzheimer Res. 2009 Feb;6(1):79-81. doi: 10.2174/156720509787313916. Curr Alzheimer Res. 2009. PMID: 19199879 Free PMC article. Review.

2

Kinetics of cholinesterase inhibition by eptastigmine in man.

Unni LK, Hutt V, Imbimbo BP, Becker RE. Unni LK, et al. Eur J Clin Pharmacol. 1991;41(1):83-4. doi: 10.1007/BF00280116. Eur J Clin Pharmacol. 1991. PMID: 1782985 No abstract available.

3

Binding of physostigmine to rat and human plasma and crystalline serum albumins.

Unni LK, Somani SM. Unni LK, et al. Life Sci. 1985 Apr 8;36(14):1389-96. doi: 10.1016/0024-3205(85)90045-1. Life Sci. 1985. PMID: 3982219

4

Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.

Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Becker RE, et al. Among authors: unni lk. Alzheimer Dis Assoc Disord. 1998 Mar;12(1):54-7. doi: 10.1097/00002093-199803000-00009. Alzheimer Dis Assoc Disord. 1998. PMID: 9539412 Clinical Trial.

5

Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.

Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Becker RE, et al. Among authors: unni lk. Alzheimer Dis Assoc Disord. 1996 Fall;10(3):124-31. doi: 10.1097/00002093-199601030-00003. Alzheimer Dis Assoc Disord. 1996. PMID: 8876775 Clinical Trial.

6

High-performance liquid chromatographic method using ultraviolet detection for measuring metrifonate and dichlorvos levels in human plasma.

Unni LK, Hannant ME, Becker RE. Unni LK, et al. J Chromatogr. 1992 Jan 3;573(1):99-103. doi: 10.1016/0378-4347(92)80480-e. J Chromatogr. 1992. PMID: 1564112

7

Inhibition of bovine plasma amine oxidase by lead.

Unni LK, Caspers ML. Unni LK, et al. Biochem Pharmacol. 1984 Jul 1;33(13):2149-51. doi: 10.1016/0006-2952(84)90587-2. Biochem Pharmacol. 1984. PMID: 6430301 No abstract available.

8

Hepatic and muscle clearance of physostigmine in the rat.

Unni LK, Somani SM. Unni LK, et al. Drug Metab Dispos. 1986 Mar-Apr;14(2):183-9. Drug Metab Dispos. 1986. PMID: 2870892

9

Physiological pharmacokinetic and pharmacodynamic model of physostigmine in the rat.

Somani SM, Gupta SK, Khalique A, Unni LK. Somani SM, et al. Among authors: unni lk. Drug Metab Dispos. 1991 May-Jun;19(3):655-60. Drug Metab Dispos. 1991. PMID: 1680633

10

Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection.

Unni LK, Becker RE. Unni LK, et al. J Chromatogr. 1992 Jan 17;573(2):275-81. doi: 10.1016/0378-4347(92)80129-e. J Chromatogr. 1992. PMID: 1601960

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results